Novo Nordisk A/S (NVO) Analysts See $0.56 EPS

January 15, 2018 - By Migdalia James

 Novo Nordisk A/S (NVO) Analysts See $0.56 EPS

Analysts expect Novo Nordisk A/S (NYSE:NVO) to report $0.56 EPS on February, 1.They anticipate $0.06 EPS change or 12.00 % from last quarter’s $0.5 EPS. NVO’s profit would be $1.35 billion giving it 24.57 P/E if the $0.56 EPS is correct. After having $0.62 EPS previously, Novo Nordisk A/S’s analysts see -9.68 % EPS growth. The stock increased 0.15% or $0.08 during the last trading session, reaching $55.04. About 1.10M shares traded. Novo Nordisk A/S (NYSE:NVO) has declined 23.93% since January 15, 2017 and is downtrending. It has underperformed by 40.63% the S&P500.

Novo Nordisk A/S (NYSE:NVO) Ratings Coverage

Among 15 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 7 have Buy rating, 0 Sell and 8 Hold. Therefore 47% are positive. Novo Nordisk (ADR) had 20 analyst reports since August 28, 2015 according to SRatingsIntel. Leerink Swann initiated the shares of NVO in report on Friday, August 28 with “Market Perform” rating. JP Morgan downgraded the shares of NVO in report on Friday, September 9 to “Neutral” rating. UBS upgraded Novo Nordisk A/S (NYSE:NVO) on Tuesday, December 6 to “Buy” rating. The company was initiated on Friday, September 23 by Piper Jaffray. The firm has “Outperform” rating by BNP Paribas given on Tuesday, September 13. J.P. Morgan upgraded the shares of NVO in report on Friday, December 29 to “Hold” rating. HSBC upgraded the shares of NVO in report on Wednesday, August 31 to “Hold” rating. The company was upgraded on Wednesday, September 6 by Bank of America. As per Monday, February 15, the company rating was upgraded by Goldman Sachs. The firm has “Sell” rating by UBS given on Monday, February 8.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $132.50 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 22.15 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

More recent Novo Nordisk A/S (NYSE:NVO) news were published by: which released: “A Peek Into The Markets: US Stock Futures Mostly Flat Ahead Of Fed Speakers” on January 08, 2018. Also published the news titled: “Why Novo Nordisk A/S (ADR) Jumped 10.6% In May” on June 10, 2017.‘s news article titled: “Here’s Why Novo Nordisk A/S Gained 12% in August” with publication date: September 06, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.